About Aldo-keto reductase family 1 member C2
Aldo-keto reductase family 1 member C2 (AKR1C2) is a protein
from Homo sapiens identified by UniProt accession
P52895, 323 residues long.
MolForge cross-references it against 0 known binders and
113 disease associations.
Target properties
| Protein name | Aldo-keto reductase family 1 member C2 |
| UniProt accession | P52895 |
| Gene | AKR1C2 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (11)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (113)
Diseases linked to this target (Open Targets).
- 46,XY disorder of sex development due to isolated 17,20 lyase deficiency · score 0.66
- 46,XY complete gonadal dysgenesis · score 0.48
- testosterone measurement · score 0.48
- body height · score 0.31
- neurofibrillary tangles measurement · score 0.29
- neurodegenerative disease · score 0.24
- lean body mass · score 0.23
- BMI-adjusted waist-hip ratio · score 0.21
- appendicular lean mass · score 0.20
- waist-hip ratio · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P52895-F1 | alphafold | PREDICTED | 96.84 | — |
Amino-acid sequence (323 residues)
MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEAVKL AIEAGFHHID SAHVYNNEEQ VGLAIRSKIA DGSVKREDIF YTSKLWSNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV SVKPGEEVIP KDENGKILFD TVDLCATWEA MEKCKDAGLA KSIGVSNFNH RLLEMILNKP GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN RNVRYLTLDI FAGPPNYPFS DEY
Explore Aldo-keto reductase family 1 member C2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets